ATORVASTATIN CALCIUM (atorvastatin calcium) by Biocon is selective, competitive inhibitor of hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a to mevalonate, a precursor of sterols, including cholesterol. Approved for type 2 diabetes mellitus, heart failure. First approved in 2022.
Drug data last refreshed 20h ago
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA…
Worked on ATORVASTATIN CALCIUM at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Actual Use Trial of Atorvastatin Calcium 10 mg
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions